

**Freedom of Information Request: Our Reference CTHB\_150\_16**

**You asked:**

**1. Do all patients, who are diagnosed with bowel cancer under the age of 50 years in your trust, have a molecular screening test for Lynch Syndrome, such as immunohistochemistry or microsatellite instability testing, carried out on tumour tissue?**

☐ **Yes**

✓ No \* only stage 2 (non node positive) colo-rectal cancers are tested.

**2. If yes, at what stage does this testing take place? Does it take place:**

☐ **Pre treatment i.e. at diagnosis (on a biopsy of the tumour)**

✓ \*Post treatment i.e. test is carried out on the tumour resection specimen - resection needed to determine if node is negative.

**3. Is this test carried out as a reflex test i.e. automatically or upon referral?**

☐ **Reflex**

✓ \* Referral via MDT

☐ **Referral via Genetics Centre**

☐ **Referral via GP**

☐ **Other (please explain)**

**4. Which of the following molecular tests does your trust use to identify people who could have Lynch syndrome:**

✓ **Microsatellite Instability (MSI)** – performed in All Wales Genetic Lab and funded by Welsh Health Specialist Services Committee (WHSSC)

☐ **Immunohistochemistry (IHC)**

☐ **BRAF and MLH1**

☐ **Other**

**5. Are the results of this reflex test communicated to the patient?**

✓ Yes

☐ **No**

**6. If no such reflex test is in place, do you have information on whether there are any plans to introduce molecular testing for Lynch syndrome?**

N/A